The Biotech Insider Trading Scandal: How Stat News Missed The Real Story
Good morning, all.
I begin with a fan letter to Stat. Since its inception last year, Stat News impressed me with its coverage of healthcare, medical academia and the biotech and pharmaceutical industries: good reporting, good writing, proofreading and editing. For a barely readable first-draft-submitting hack amateur like myself, Stat leads by example. (In fact, just a few days ago I emailed Rick Berke, the Stat executive editor, offering to write a barely readable first-draft submission for them if they needed one. Haven’t heard back yet.)
I begin with a fan letter to Stat. Since its inception last year, Stat News impressed me with its coverage of healthcare, medical academia and the biotech and pharmaceutical industries: good reporting, good writing, proofreading and editing. For a barely readable first-draft-submitting hack amateur like myself, Stat leads by example. (In fact, just a few days ago I emailed Rick Berke, the Stat executive editor, offering to write a barely readable first-draft submission for them if they needed one. Haven’t heard back yet.)